Background: Acquired tamoxifen resistance is one of the major barriers to the successful treatment of breast cancer. Recently, overexpression of ERα 36 was demonstrated to be a potential mechanism for the generation of acquired tamoxifen resistance. This study aims to evaluate the possibility of ERα 36 being a therapeutic target for tamoxifen-resistant breast cancer.
Methods: A tamoxifen-resistant cell subline (MCF-7/TAM) was established by culturing MCF-7 cells in medium plus 1 μM tamoxifen over 6 months. Colony-forming assay was used to determine the sensitivity of MCF-7/TAM cells to tamoxifen. Stable transfection was used to knockdown ERα 36 expression in MCF-7/TAM cells. MTT assay and Transwell migration assay were used to assess the in vitro proliferation and migration, respectively. Nude mouse tumorigenicity assay was used to evaluate in vivo tumorigenicity. Western blot analysis and quantitative real-time PCR (qRT-PCR) were used to examine the expression of ERα 36, ERα, EGFR and phosphorylated ERK1/2. The dual-luciferase reporter assay was used to determine the effect of ERα 36 on the activity of EGFR -promotor.
Results: MCF-7/TAM cells possessed greatly increased ERα 36 expression and EGFR expression and exhibited significantly increased in vitro proliferation and migration ability, as well as increased in vivo tumor growth ability, compared to parental MCF-7 cells. Knockdown of ERα 36 expression inhibited in vitro proliferation and migration, as well as in vivo tumor growth ability of MCF-7/TAM cells. ERα 36 regulated EGFR expression at the transcriptional level, and knockdown of ERα 36 in MCF-7/TAM cells downregulated EGFR expression and then blocked EGFR/ERK signaling pathway.
Conclusion: Knockdown of ERα 36 inhibits the growth of MCF-7/TAM cells in vitro and in vivo by blocking EGFR/ERK signaling pathway. ERα 36 may be a candidate therapeutic target for the treatment of tamoxifen-resistant breast cancer.
Keywords: breast cancer, acquired tamoxifen resistance, ERα 36, EGFR/ERK signalling